DAWN Stock Price, Day One Biopharmaceuticals, . Quote, Chart

Market Summary

USD14.91+1.70

Market Closed

12.87%

DAWN Alerts

1 major insider sales recently.

DAWN Stock Price

View Fullscreen

DAWN RSI Chart

DAWN Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

-6.9

Price/Sales (Trailing)

75.81

Price/Free Cashflow

-8.86

DAWN Price/Sales (Trailing)

DAWN Profitability

Return on Equity

-54.52%

Return on Assets

-50.24%

Free Cashflow Yield

-11.29%

DAWN Fundamentals

DAWN Revenue

Revenue (TTM)

17.2M

Rev. Growth (Yr)

88.87%

Rev. Growth (Qtr)

-5.05%

DAWN Earnings

Earnings (TTM)

-188.9M

Earnings Growth (Yr)

-35.91%

Earnings Growth (Qtr)

-18.12%

Breaking Down DAWN Revenue

Last 7 days

-0.3%

Last 30 days

-5.6%

Last 90 days

4.9%

Trailing 12 Months

23.2%

How does DAWN drawdown profile look like?

DAWN Financial Health

Current Ratio

12.72

DAWN Investor Care

Shares Dilution (1Y)

18.35%

Diluted EPS (TTM)

-2.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.2M	11.4M	14.8M	17.2M
2022	0	0	0	4.7M
2021	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Day One Biopharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	blackman samuel c.	sold	-160,163	16.0163	-10,000	head of r&d
Mar 25, 2024	blackman samuel c.	sold	-160,055	16.0055	-10,000	head of r&d
Mar 11, 2024	blackman samuel c.	sold	-457,314	15.2438	-30,000	head of r&d
Feb 27, 2024	blackman samuel c.	sold	-322,166	16.1083	-20,000	head of r&d
Feb 16, 2024	bender jeremy	sold	-116,114	15.2481	-7,615	chief executive officer
Feb 16, 2024	york charles n ii	sold	-40,651	15.2481	-2,666	coo, cfo and secretary
Feb 16, 2024	blackman samuel c.	sold	-34,430	15.2481	-2,258	head of research and developme
Feb 16, 2024	dubow adam	sold	-49,434	15.2481	-3,242	general counsel
Feb 15, 2024	dubow adam	acquired	-	-	8,399	general counsel
Feb 15, 2024	bender jeremy	acquired	-	-	19,999	chief executive officer

Which funds bought or sold DAWN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	45,000	45,000	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	13,398	115,277	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-8.03	138,838	3,558,130	-%
Apr 24, 2024	Spire Wealth Management	unchanged	-	104	661	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-75.11	-90,000	35,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	77,922	488,268	-%
Apr 19, 2024	Red Tortoise LLC	unchanged	-	376	3,238	-%
Apr 17, 2024	Hennion & Walsh Asset Management, Inc.	added	2.5	134,932	979,454	0.05%
Apr 16, 2024	TSFG, LLC	new	-	50,000	50,000	0.01%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	99.36	184,671	331,722	0.01%

Are Funds Buying or Selling DAWN?

Are funds buying DAWN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DAWN

No. of Funds

DAWN Alerts

1 major insider sales recently.

Unveiling Day One Biopharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.0%	7,809,852	SC 13G/A
Feb 13, 2024	vanguard group inc	5.48%	4,769,746	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	atlas venture fund xi, l.p.	6.9%	6,008,534	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	5,126,071	SC 13G
Oct 20, 2023	ai day1 llc	14.87%	12,929,322	SC 13D/A
Aug 10, 2023	fmr llc	-	0	SC 13G/A
Jun 12, 2023	ai day1 llc	13.19%	11,453,868	SC 13D/A
Feb 14, 2023	ra capital management, l.p.	9.6%	7,040,622	SC 13G/A
Feb 14, 2023	atlas venture fund xi, l.p.	8.2%	6,008,534	SC 13G/A

Recent SEC filings of Day One Biopharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	8-K	Current Report
Apr 22, 2024	4	Insider Trading
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Mar 26, 2024	4	Insider Trading
Mar 13, 2024	4	Insider Trading
Mar 07, 2024	8-K	Current Report
Feb 28, 2024	4	Insider Trading
Feb 27, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Day One Biopharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Day One Biopharmaceuticals, Inc. News

Latest updates

Day One Biopharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	-5.0%	5,024	5,291	3,406	3,466	2,660	1,895	189	-	-
Operating Expenses	15.7%	59,517	51,438	49,254	45,855	42,743	39,699	36,719	27,748	21,976
S&GA Expenses	21.3%	22,169	18,275	17,072	18,027	16,723	17,664	14,159	12,745	10,787
R&D Expenses	12.6%	37,348	33,163	32,182	27,828	26,020	22,035	22,560	15,003	11,189
Interest Expenses	-	-	-	-	-	2,660	1,895	189	2.00	24.00
Net Income	-18.1%	-54,511	-46,150	-45,863	-42,393	-40,109	-37,795	-36,530	-27,747	-22,993
Net Income Margin	6.6%	-10.99*	-11.77*	-14.54*	-19.10*	-29.96*	-	-	-	-
Free Cashflow	-11.5%	-41,380	-37,105	-42,581	-26,011	-35,310	-23,218	-29,794	-21,578	-13,169

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-9.2%	376	414	451	324	349	382	404	268	290	304	317	46.00
Current Assets	-9.2%	375	413	450	-	348	-	-	-	289	-	-	45.00
Cash Equivalents	-4.3%	231	241	189	49.00	85.00	121	389	263	284	297	310	44.00
Net PPE	-2.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	20.2%	30.00	25.00	25.00	23.00	17.00	19.00	13.00	8.00	9.00	6.00	5.00	2.00
Current Liabilities	20.6%	30.00	24.00	25.00	23.00	17.00	18.00	13.00	8.00	9.00	6.00	5.00	2.00
Shareholder's Equity	-11.1%	347	390	426	300	332	363	391	260	281	298	312	-54.20
Retained Earnings	-13.5%	-458	-404	-357	-312	-269	-229	-191	-155	-127	-105	-86.31	-56.84
Additional Paid-In Capital	1.4%	805	794	784	612	602	593	582	415	409	403	398	-
Shares Outstanding	0.2%	87.00	87.00	87.00	74.00	73.00	64.00	60.00	58.00	37.00	30.00	23.00	6.00
Float	-	-	-	759	-	-	-	698	-	-	-	646	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-11.6%	-41,372	-37,064	-42,432	-25,985	-35,310	-23,214	-29,787	-21,563	-13,169	-12,221	-13,406	-9,743	-5,938	-3,578	-	-
Share Based Compensation	12.5%	10,811	9,606	9,477	9,447	6,833	8,576	5,631	6,202	5,097	5,149	2,537	538	350	60.00	57.00	-
Cashflow From Investing	-65.8%	30,380	88,917	20,274	-11,193	-2,210	-246,852	-5,997	-15.00	-	-	-	-8,000	1.00	-	-	-
Cashflow From Financing	419.1%	597	115	162,101	1,184	1,918	2,053	161,930	-	318	-615	168,532	128,885	-	-	-	-

DAWN Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research And Development Expense	$ 130,521	$ 85,618	$ 43,584
General and administrative	75,543	61,291	29,159
Total operating expenses	206,064	146,909	72,743
Loss from operations	(206,064)	(146,909)	(72,743)
Investment Income, Net	17,187	4,746	4
Other expense, net	(40)	(18)	(15)
Net loss	(188,917)	(142,181)	(72,754)
Net loss attributable to redeemable convertible noncontrolling interests	0	0	(2,109)
Exchange of redeemable noncontrolling interest shares-deemed dividend	0	0	(99,994)
Net loss attributable to common stockholders/members	$ (188,917)	$ (142,181)	$ (170,639)
Net loss per share, basic	$ (2.37)	$ (2.17)	$ (4.62)
Net loss per share, diluted	$ (2.37)	$ (2.17)	$ (4.62)
Weighted-average number of common shares used in computing net loss per share, basic	79,773,004	65,466,773	36,960,569
Weighted-average number of common shares used in computing net loss per share, diluted	79,773,004	65,466,773	36,960,569

DAWN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 230,784	$ 85,262
Short-term investments	135,563	257,007
Prepaid expenses and other current assets	8,927	5,605
Total current assets	375,274	347,874
Property and equipment, net	208	20
Operating lease right-of-use asset	352	699
Deposits and other long-term assets	214	469
Total assets	376,048	349,062
Current liabilities:
Accounts payable	2,576	260
Accrued expenses and other current liabilities	26,524	15,950
Current portion of operating lease liabilities	408	405
Total current liabilities	29,508	16,615
Long-term portion of lease liabilities	0	408
Total liabilities	29,508	17,023
Commitments and contingencies (Note 6)
Stockholders' equity
Common stock, $0.001 par value; 500,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 87,227,132 and 73,458,176 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	9	7
Additional paid-in-capital	805,107	601,771
Accumulated other comprehensive loss	9	(71)
Accumulated deficit	(458,585)	(269,668)
Total stockholders' equity	346,540	332,039
Total liabilities and stockholders' equity	$ 376,048	$ 349,062

About Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

CEO	Dr. Jeremy Bender M.B.A., Ph.D.
WEBSITE	https://dayonebio.com
INDUSTRY	Biotechnology
EMPLOYEES	124

Day One Biopharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Day One Biopharmaceuticals, Inc.? What does DAWN stand for in stocks?

DAWN is the stock ticker symbol of Day One Biopharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Day One Biopharmaceuticals, Inc. (DAWN)?

As of Fri Apr 26 2024, market cap of Day One Biopharmaceuticals, Inc. is 1.3 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DAWN stock?

You can check DAWN's fair value in chart for subscribers.

What is the fair value of DAWN stock?

You can check DAWN's fair value in chart for subscribers. The fair value of Day One Biopharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Day One Biopharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DAWN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Day One Biopharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether DAWN is over valued or under valued. Whether Day One Biopharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Day One Biopharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DAWN.

What is Day One Biopharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, DAWN's PE ratio (Price to Earnings) is -6.9 and Price to Sales (PS) ratio is 75.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DAWN PE ratio will change depending on the future growth rate expectations of investors.